2417491-82-6
Chemical Structure
Gersizangitide
Synonym(s): AXT-107
- CAS No.: 2417491-82-6
- Formula:C111H167N29O28
- Molecular Weight:2355.69
InChIKey: VNWKTOKETHGBQD-UHFFFAOYSA-N
SMILES: NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC2=CC=CC=C2)NC([C@H](C)NC([C@H](CC3=CC=CC=C3)NC([C@H]4N(CCC4)C([C@H](C)NC([C@H]([C@H](O)C)NC([C@H](CO)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@@H](N)CC(C)C)=O)=O)=O)CC5=CC=CC=C5)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGF receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gersizangitide | 97.16% | Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGF receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Fei X, et al. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration. Arch Pharm Res. 2024 Jun;47(6):538-557. [Content Brief]
- [2]. Mirando AC, et al. A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling. JCI Insight. 2019 Feb 21;4(4):e122043. [Content Brief]
Keywords